Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Invyncible vs Tablet Health

Invyncible
Graded #303

Higher grade

vs+13.399999999999999
Tablet Health
Graded #495

Lower grade

The verdict

Invyncible takes it — 61/100 to 47.6/100.

Invyncible grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Invyncible is a Florida-based telehealth platform offering semaglutide and tirzepatide programs for weight management.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueInvyncible +10
55
45
Dose & formulationInvyncible +13
64
51
Clinical oversightInvyncible +33
70
37
Labs & monitoringInvyncible +2
52
50
FulfillmentInvyncible +8
65
57
Contract termsInvyncible +6
61
55
Invyncible · left barTablet Health · right bar

The numbers

MetricInvyncibleTablet Health
WeighScore61/10047.6/100
GradeCC
Scorecard rank#303#495
Semaglutide$192/mo (0.5 mg dose, compounded)Not disclosed
Tirzepatide$210/mo (compounded)Not disclosed
Coverage40 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Invyncible

Graded #303 · C

Strengths

  • Corporate parent disclosed (Nationwide Telemedicine, LLC) — better than most competitors hiding behind trade names
  • Physical corporate address published (St. Petersburg, FL)
  • LegitScript verification seal displayed
  • No long-term commitment required
  • Offers both semaglutide and tirzepatide programs

Where it loses points

  • Pricing not disclosed on the public site — fully gated behind signup
  • Drug forms (compounded vs brand, injection vs oral) not disclosed
  • 503A vs 503B designation not specified
  • Pharmacy partner not named
  • States served not listed publicly
Tablet Health

Graded #495 · C

Strengths

  • LegitScript Certified
  • Four named compounding pharmacy partners (Pharmacy Hub, Epiq Scripts, Dr. TelX, Emerad), none with FDA warning letters
  • Oral GLP-1 option for both semaglutide and tirzepatide — uncommon in compounded telehealth
  • Mid-tier pricing starting $179–$299/mo across all four product variants
  • No commitment — cancel anytime

Where it loses points

  • States served not published — you must complete the intake quiz to learn eligibility
  • No founder, CEO, medical director, or pharmacist-in-charge named anywhere
  • No BBB profile found
  • Its Queens NYC pharmacy is 'opening soon' — all dispensing currently routes through external partners
  • FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard